Liver cancer early diagnosis kit convenient to use and store
By combining benzenesulfonate derivatives with ZnO quantum dots and a kit design for easy use, the problems of reagent damage and contamination in the prior art are solved, and the accuracy of diagnosis and convenience of use are improved.
Patent Information
- Application Number
- CN202411889448.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-20
- Publication Date
- 2025-03-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing liver cancer diagnosis kits are prone to damage and contamination of the reagent during operation, and there are operational deviations in pathological staining, which affects the accuracy of diagnosis.
Early diagnosis reagents for liver cancer that bind to ZnO quantum dots based on metabolic fluorescence, and design a kit for easy use and storage to avoid reagent collision and contamination through structures such as card blocks and limit blocks.
It improves the accuracy of early diagnosis of liver cancer, avoids reagent damage and contamination, and simplifies the use and storage process of reagents.
Smart Images
Figure CN119709176A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of diagnostic kits, and in particular to an early diagnosis kit for liver cancer which is convenient to use and store. Background Art
[0002] Diagnostic kits are boxes that can perform qualitative and quantitative tests on human body fluids, blood and other substances that reflect human health conditions, and are used to hold chemical reagents for testing chemical components, drug residues, virus types, etc. They are generally used in hospitals and pharmaceutical companies, and are often used for the use and storage of early diagnosis reagents for liver cancer.
[0003] Existing liver cancer diagnosis generally relies on pathological diagnosis. However, pathological diagnosis often makes it difficult to distinguish healthy cells from cancer cells due to operational reasons during pathological staining. In addition, the level of each operating physician may be different, resulting in certain deviations in specific judgments. Cancer screening is very important for patients, so it is necessary to provide a more accurate reagent for distinguishing cancer cells from healthy cells to make a more obvious qualitative diagnosis.
[0004] In addition, the existing diagnostic kits do not have a device to isolate individual reagents, so when the reagents are placed in the placement box and the placement box is moved, the shaking caused by the shaking can easily cause collisions between the internal reagents, leading to the risk of damage. Once a single reagent is broken, it can easily contaminate the surrounding reagents, which is very inconvenient during use. For this reason, we also propose an early liver cancer diagnosis kit that is easy to use and store. Summary of the invention
[0005] In view of the above content, in order to solve the above problems, a benzenesulfonate anthraquinone derivative ZnO quantum dot liver cancer early diagnosis reagent based on metabolic fluorescence is provided.
[0006] The chemical formula of benzenesulfonic acid anthraquinone derivative is:
[0007]
[0008] The quantum dot combination mode of benzenesulfonic acid anthraquinone derivative and ZnO is:
[0009] Add ZnO nanopowder into a beaker and heat it to 100℃ to boil. Then place the mixed liquid of ZnO and water under a femtosecond laser for laser ablation. The ablation power is 150-200W and the laser spot is 1-2.5cm. 2 , laser frequency 1-15kHz, ablation to ZnO quantum dots with a particle size of less than 2nm;
[0010] The ablated ZnO quantum dots are cooled to room temperature and then mixed with benzenesulfonate anthraquinone derivatives to a fixed volume of 1 L. The mass ratio of ZnO in the mixture is 3-6%, and the mass ratio of benzenesulfonate anthraquinone derivatives is 1-2%. After mixing, 2-5 ml of triphenylphosphine and mercapto polypropylene glycol are added, and then stirred rapidly. During stirring, the mixture is heated slowly to a temperature of 35-40° C. and kept warm for 15-30 minutes. The benzenesulfonate anthraquinone derivatives are connected to the ZnO quantum dots to obtain the obtained product.
[0011] The preparation method of benzenesulfonic acid anthraquinone derivatives is as follows:
[0012] Mixing compound A, compound B and anthraquinone, and reacting after mixing;
[0013] The chemical formula of compound A is:
[0014]
[0015] The chemical formula of compound B is:
[0016]
[0017] Compound A, compound B and anthraquinone were added in sequence to a glass reactor, wherein the ratio of compound A, compound B and anthraquinone was 0.8:1:1.5, anhydrous sodium bicarbonate, and then ethylene glycol was added, and the reaction was carried out in a water bath at 57°C, and then added to ice water at 0°C; then, silica gel column chromatography was used for purification, and the eluent was (dichloromethane: petroleum ether = 1:1) to obtain a transparent product.
[0018] During the test, the living cells just removed are soaked in the diagnostic reagent for 10 to 15 minutes, and then soaked in warm water at 35 to 40°C for 10 to 15 minutes; then frozen sections are taken. Since the benzenesulfonic acid anthraquinone derivatives in the reagent cannot penetrate cancer cells but can penetrate healthy cells, when observed under a fluorescence microscope, if there is ZnO and anthraquinone fluorescence inside the cell, it means that it is a healthy cell; if there is weak ZnO fluorescence inside the cell and no anthraquinone fluorescence, but strong ZnO and anthraquinone fluorescence on the periphery of the cell, it means that it is a cancer cell.
[0019] Further, a liver cancer early diagnosis kit that is easy to use and store is provided, comprising a placement box and a card block, wherein a fixed frame is fixedly installed on the inner bottom wall of the placement box, and a shielding cover is slidably connected to the inner wall of the placement box, a connecting groove matched with the card block is provided on the top of the fixed frame, a fixed block is fixedly installed on the side wall of the shielding cover, a connecting ring is clamped on the surface of the fixed block, and a connecting block is rotatably connected to the bottom end of the connecting ring, a plurality of limit blocks are fixedly installed on the inner wall of the fixed frame, and slots are provided on the tops of the plurality of limit blocks, an auxiliary block is fixedly connected to the side wall of the fixed frame, and a shielding block is movably connected to the top of the auxiliary block, a storage box is fixedly installed on the top of the shielding cover, a rotating cover is rotatably connected to one side of the storage box, the size of the shielding cover surface is matched with the size of the inner wall of the placement box, the bottom end of the card block is clamped with the inner wall of the connecting groove, and the size of the bottom end of the card block is matched with the size of the inner wall of the connecting groove, and the top of the card block is fixedly installed with the bottom end of the shielding cover.
[0020] The kit works as follows:
[0021] The card block is installed at the bottom of the shielding cover. After the reagents are placed in, the card block is connected to the connecting groove on the top of the fixed frame to separate the medicines in the placement box, thereby avoiding the risk of damage caused by the shaking when the reagents are placed in the placement box and the placement box is carried. In addition, when a single reagent is broken, it is easy to contaminate the surrounding reagents, which is very inconvenient during use.
[0022] In a further technical solution, there are at least two fixed blocks, which are symmetrically distributed with the shielding cover as the axis, and the cross-sections of the two fixed blocks are both "L"-shaped, the cross-section of the connecting ring is "U"-shaped, and one side of the connecting block is fixedly connected to the surface of the placement box.
[0023] After the shielding cover is placed in the placement box, the clamping ring is clamped on the fixing block to fix the shielding cover on the placement box, thereby preventing the shielding cover from loosening and causing poor shielding effect of the clamping block.
[0024] In a further technical solution, the size of the surface of the limit block is matched with the size of the inner wall of the fixing frame, and the limit block is a rubber block, and the center of the slot and the center of the limit block are on the same straight line.
[0025] Insert the reagent into the slot in the rubber limit block to fix the reagent in the fixing frame to avoid the problem of taking the reagent out when the card block is taken out.
[0026] In a further technical solution, the side wall of the auxiliary block is movably mounted on the inner wall of the placement box, and the auxiliary block is a sponge block. The size of the surface of the auxiliary block is compatible with the size of the inner wall of the placement box. The shielding block is a rubber block, and the top of the shielding block is fixedly connected to the bottom of the shielding cover.
[0027] The auxiliary block made of sponge material absorbs the broken reagent solution, and the shielding block shields the gap between the shielding cover and the placement box to avoid contamination of the surrounding placement boxes and to prevent the reagent from leaking out of the placement box.
[0028] In a further technical solution, the center of the storage box and the center of the shielding cover are on the same straight line, and the size specification of the inner wall of the rotating cover is compatible with the size specification of the surface of the storage box.
[0029] The storage box is installed on the upper end of the shielding cover, and the patient's information is placed inside the storage box. The cover is rotated to shield the patient so that the patient's information can be saved and the patient's information can be found in time when in use, which is more convenient when in use.
[0030] In a further technical solution, a partition plate is fixedly installed inside the storage box, and the size specification of the surface of the partition plate is matched with the size specification of the inner wall of the storage box.
[0031] The partition board subdivides the space in the storage box to facilitate the organization of the information inside the storage box.
[0032] The beneficial effects of the present invention are:
[0033] 1. A new liver cancer detection reagent is provided. The benzenesulfonic acid anthraquinone derivative in the reagent cannot penetrate cancer cells but can penetrate healthy cells. Therefore, when observing under a fluorescence microscope, if there is ZnO and anthraquinone fluorescence inside the cell, it means that it is a healthy cell; if there is weak ZnO fluorescence inside the cell and no anthraquinone fluorescence, but strong ZnO and anthraquinone fluorescence outside the cell, it means that it is a cancer cell.
[0034] 2. The card block is installed at the bottom of the shielding cover. After the reagents are placed, the card block is connected to the connecting groove at the top of the fixed frame to separate the reagents in the placement box, thereby avoiding the risk of damage caused by the shaking when the reagents are placed in the placement box and the placement box is carried. In addition, when a single reagent is broken, it is easy to contaminate the surrounding reagents, which is very inconvenient during use;
[0035] 3. After putting the shielding cover into the placement box, clamp the clamp ring on the fixed block to fix the shielding cover on the placement box, so as to avoid the shielding cover being loose and causing poor shielding effect of the block. Insert the reagent into the slot in the rubber limit block to fix the reagent in the fixed frame to avoid the problem of taking out the reagent when the block is taken out. The auxiliary block of sponge material absorbs the broken reagent solution, and the shielding block blocks the gap between the shielding cover and the placement box to avoid contamination of the surrounding placement box and prevent the reagent from leaking out of the placement box.
[0036] 4. The storage box is installed on the upper end of the shielding cover, and the patient's information is placed inside the storage box. The cover is rotated to shield the patient so as to save the patient's information. The patient's information can be found in time when in use, which is more convenient to use. The partition plate subdivides the space inside the storage box to organize the information inside the storage box. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 is a schematic diagram of the overall structure of an embodiment of the present invention;
[0038] Figure 2 is a schematic diagram of the enlarged structure of point A in an embodiment of the present invention;
[0039] Figure 3 is a schematic diagram of the card block structure of an embodiment of the present invention;
[0040] Figure 4 is a schematic side view of the structure of an embodiment of the present invention;
[0041] Figure 5 It is a schematic diagram of the enlarged structure of point B in an embodiment of the present invention.
[0042] Description of reference numerals:
[0043] 1. Placement box; 2. Fixed frame; 3. Shielding cover; 4. Card block; 5. Connection groove; 6. Fixed block; 7. Connecting ring; 8. Connecting block; 9. Limiting block; 10. Slot; 11. Auxiliary block; 12. Shielding block; 13. Storage box; 14. Rotating cover; 15. Partition plate. DETAILED DESCRIPTION
[0044] The advantages, features and methods of achieving the above objects of the present invention will become clear from the accompanying drawings and the following detailed description.
[0045] Embodiment 1:
[0046] A metabolic fluorescence-based early diagnostic reagent for liver cancer based on benzenesulfonate anthraquinone derivative ZnO quantum dots.
[0047] The chemical formula of benzenesulfonic acid anthraquinone derivative is:
[0048]
[0049] The quantum dot combination mode of benzenesulfonic acid anthraquinone derivative and ZnO is:
[0050] Add ZnO nanopowder into a beaker and heat it to 100℃ to boil. Then place the mixed liquid of ZnO and water under a femtosecond laser for laser ablation. The ablation power is 150-200W and the laser spot is 1-2.5cm. 2 , laser frequency 1-15kHz, ablation to ZnO quantum dots with a particle size of less than 2nm;
[0051] The ablated ZnO quantum dots are cooled to room temperature and then mixed with benzenesulfonate anthraquinone derivatives to a fixed volume of 1 L. The mass ratio of ZnO in the mixture is 3-6%, and the mass ratio of benzenesulfonate anthraquinone derivatives is 1-2%. After mixing, 2-5 ml of triphenylphosphine and mercapto polypropylene glycol are added, and then stirred rapidly. During stirring, the mixture is heated slowly to a temperature of 35-40° C. and kept warm for 15-30 minutes. The benzenesulfonate anthraquinone derivatives are connected to the ZnO quantum dots to obtain the obtained product.
[0052] The preparation method of benzenesulfonic acid anthraquinone derivatives is as follows:
[0053] Mixing compound A, compound B and anthraquinone, and reacting after mixing;
[0054] The chemical formula of compound A is:
[0055]
[0056] The chemical formula of compound B is:
[0057]
[0058] Compound A, compound B and anthraquinone were added in sequence to a glass reactor, wherein the ratio of compound A, compound B and anthraquinone was 0.8:1:1.5, anhydrous sodium bicarbonate, and then ethylene glycol was added, and the reaction was carried out in a water bath at 57°C, and then added to ice water at 0°C; then, silica gel column chromatography was used for purification, and the eluent was (dichloromethane: petroleum ether = 1:1) to obtain a transparent product.
[0059] During the test, the living cells just removed are soaked in the diagnostic reagent for 10 to 15 minutes, and then soaked in warm water at 35 to 40°C for 10 to 15 minutes; then frozen sections are taken. Since the benzenesulfonic acid anthraquinone derivatives in the reagent cannot penetrate cancer cells but can penetrate healthy cells, when observed under a fluorescence microscope, if there is ZnO and anthraquinone fluorescence inside the cell, it means that it is a healthy cell; if there is weak ZnO fluorescence inside the cell and no anthraquinone fluorescence, but strong ZnO and anthraquinone fluorescence on the periphery of the cell, it means that it is a cancer cell.
[0060] Embodiment 2:
[0061] like Figure 1-Figure 5 As shown, a liver cancer early diagnosis kit that is easy to use and store includes a placement box 1 and a card block 4. A fixing frame 2 is fixedly installed on the inner bottom wall of the placement box 1, and a shielding cover 3 is slidably connected to the inner wall of the placement box 1. A connecting groove 5 adapted to the card block 4 is opened on the top of the fixing frame 2. A fixing block 6 is fixedly installed on the side wall of the shielding cover 3. A connecting ring 7 is clamped on the surface of the fixing block 6. A connecting block 8 is rotatably connected to the bottom end of the connecting ring 7. A plurality of limit blocks 9 are fixedly installed on the inner wall of the fixing frame 2. The top of the plurality of limit blocks 9 A slot 10 is provided on each of the fixed frames 2, an auxiliary block 11 is fixedly connected to the side wall of the fixed frame 2, a shielding block 12 is movably connected to the top of the auxiliary block 11, a storage box 13 is fixedly installed on the top of the shielding cover 3, a rotating cover 14 is rotatably connected to one side of the storage box 13, the size of the surface of the shielding cover 3 is compatible with the size of the inner wall of the placement box 1, the bottom end of the card block 4 is clamped with the inner wall of the connecting groove 5, and the size of the bottom end of the card block 4 is compatible with the size of the inner wall of the connecting groove 5, and the top of the card block 4 is fixedly installed with the bottom end of the shielding cover 3.
[0062] The card block 4 is installed at the bottom of the shielding cover 3. After the reagents are placed in, the card block 4 is connected to the connecting groove 5 at the top of the fixed frame 2 to separate the medicines in the placement box 1, thereby avoiding the risk of damage caused by the shaking when the reagents are placed in the placement box 1 and the placement box 1 is carried. In addition, when a single reagent is broken, it is easy to contaminate the surrounding reagents, which is very inconvenient during use.
[0063] In another embodiment, if Figure 1 As shown, there are at least two fixed blocks 6, which are symmetrically distributed with the shielding cover 3 as the axis. The cross-sections of the two fixed blocks 6 are both "L"-shaped, the cross-section of the connecting ring 7 is "U"-shaped, and one side of the connecting block 8 is fixedly connected to the surface of the placement box 1.
[0064] After the shielding cover 3 is placed in the placement box 1 , the clamping ring is clamped on the fixing block 6 to fix the shielding cover 3 on the placement box 1 , thereby preventing the shielding cover 3 from loosening and causing the clamping block 4 to have a poor shielding effect.
[0065] In another embodiment, if Figure 1 As shown, the size of the surface of the limit block 9 is compatible with the size of the inner wall of the fixing frame 2, and the limit block 9 is a rubber block. The center of the slot 10 and the center of the limit block 9 are on the same straight line.
[0066] The reagent is inserted into the slot 10 in the rubber limiting block 9 so as to fix the reagent in the fixing frame 2 to avoid the problem of taking the reagent out when the card block 4 is taken out.
[0067] In another embodiment, if Figure 1 As shown, the side wall of the auxiliary block 11 is movably installed with the inner wall of the placement box 1, and the auxiliary block 11 is a sponge block. The size of the surface of the auxiliary block 11 is compatible with the size of the inner wall of the placement box 1. The shielding block 12 is a rubber block, and the top of the shielding block 12 is fixedly connected to the bottom end of the shielding cover 3.
[0068] The auxiliary block 11 made of sponge material absorbs the broken reagent solution, and the shielding block 12 shields the gap between the shielding cover 3 and the placement box 1 to avoid contamination of the surrounding placement box 1 and to prevent the reagent from leaking out of the placement box.
[0069] In another embodiment, if Figure 4 As shown, the center of the storage box 13 and the center of the shielding cover 3 are on the same straight line, and the size of the inner wall of the rotating cover 14 is compatible with the size of the surface of the storage box 13.
[0070] The storage box 13 is installed on the upper end of the shielding cover 3, and the patient's information is placed inside the storage box 13. The rotating cover 14 is rotated to shield the patient so that the patient's information can be saved and the patient's information can be found in time when in use, which is more convenient when in use.
[0071] In another embodiment, if Figure 4 As shown, a partition plate 15 is fixedly installed inside the storage box 13 , and the size of the surface of the partition plate 15 is compatible with the size of the inner wall of the storage box 13 .
[0072] The partition plate 15 subdivides the space in the storage box 13 so as to organize the information inside the storage box 13 .
[0073] The working principle and use process of the present invention are as follows: the card block 4 is installed at the bottom of the shielding cover 3. After the reagents are placed in, the card block 4 is connected to the connecting groove 5 at the top of the fixing frame 2 to separate the medicines in the placing box 1, thereby avoiding the risk of damage caused by the shaking when the reagents are placed in the placing box 1 and the placing box 1 is carried. In addition, when a single reagent is broken, it is easy to contaminate the surrounding reagents, which is very inconvenient during use. After the shielding cover 3 is placed in the placing box 1, the card block 4 is connected to the connecting groove 5 at the top of the fixing frame 2 to separate the medicines in the placing box 1. The ring is clamped on the fixing block 6 to facilitate fixing the shielding cover 3 on the placement box 1, thereby preventing the shielding cover 3 from loosening and causing poor shielding effect of the card block 4. The reagent is inserted into the slot 10 in the rubber limit block 9 to facilitate fixing the reagent in the fixing frame 2 to avoid the problem of taking out the reagent when the card block 4 is taken out. The auxiliary block 11 of the sponge material absorbs the broken reagent solution, and the shielding block 12 blocks the gap between the shielding cover 3 and the placement box 1 to avoid contamination of the surrounding placement box 1 and prevent the reagent from leaking out of the placement box.
[0074] The above embodiments only express the specific implementation of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the present invention. It should be pointed out that for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.
[0075] The above is only a preferred embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. A metabolic fluorescence-based benzenesulfonic acid anthraquinone derivative ZnO quantum dot liver cancer early diagnosis reagent, characterized in that: The chemical formula of benzenesulfonic acid anthraquinone derivative is: The quantum dot combination mode of benzenesulfonic acid anthraquinone derivative and ZnO is: Add ZnO nanopowder into a beaker and heat it to 100℃ to boil. Then place the mixed liquid of ZnO and water under a femtosecond laser for laser ablation. The ablation power is 150-200W and the laser spot is 1-2.5cm. 2 , laser frequency 1-15kHz, ablation to ZnO quantum dots with a particle size of less than 2nm; The ablated ZnO quantum dots are cooled to room temperature and then mixed with benzenesulfonate anthraquinone derivatives to a fixed volume of 1 L. The mass ratio of ZnO in the mixture is 3-6%, and the mass ratio of benzenesulfonate anthraquinone derivatives is 1-2%. After mixing, 2-5 ml of triphenylphosphine and mercapto polypropylene glycol are added, and then stirred rapidly. During stirring, the mixture is heated slowly to a temperature of 35-40° C. and kept warm for 15-30 minutes. The benzenesulfonate anthraquinone derivatives are connected to the ZnO quantum dots to obtain the obtained product.
2. The metabolic fluorescence-based benzenesulfonic acid anthraquinone derivative ZnO quantum dot liver cancer early diagnosis reagent according to claim 1, characterized in that: The preparation method of benzenesulfonic acid anthraquinone derivatives is as follows: Mixing compound A, compound B and anthraquinone, and reacting after mixing; The chemical formula of compound A is: The chemical formula of compound B is: Compound A, compound B and anthraquinone were added in sequence to a glass reactor, wherein the ratio of compound A, compound B and anthraquinone was 0.8:1:1.5, anhydrous sodium bicarbonate, and then ethylene glycol was added, and the reaction was carried out in a water bath at 57°C, and then added to ice water at 0°C; then, silica gel column chromatography was used for purification, and the eluent was (dichloromethane: petroleum ether = 1:1) to obtain a transparent product.
3. The metabolic fluorescence-based benzenesulfonic acid anthraquinone derivative ZnO quantum dot liver cancer early diagnosis reagent according to claim 1, characterized in that: During the test, the living cells just removed are soaked in the diagnostic reagent for 10 to 15 minutes, and then soaked in warm water at 35 to 40°C for 10 to 15 minutes; then frozen sections are taken. Since the benzenesulfonic acid anthraquinone derivatives in the reagent cannot penetrate cancer cells but can penetrate healthy cells, when observed under a fluorescence microscope, if there is ZnO and anthraquinone fluorescence inside the cell, it means that it is a healthy cell; if there is weak ZnO fluorescence inside the cell and no anthraquinone fluorescence, but strong ZnO and anthraquinone fluorescence on the periphery of the cell, it means that it is a cancer cell.
4. A kit for early diagnosis of liver cancer that is easy to use and store, characterized in that: The early diagnosis reagent for liver cancer according to any one of claims 1 to 3 further comprises a placement box (1) and a card block (4), wherein a fixing frame (2) is fixedly mounted on the inner bottom wall of the placement box (1), and a shielding cover (3) is slidably connected to the inner wall of the placement box (1), a connecting groove (5) adapted to the card block (4) is provided on the top of the fixing frame (2), a fixing block (6) is fixedly mounted on the side wall of the shielding cover (3), a connecting ring (7) is clamped on the surface of the fixing block (6), and the connecting ring The bottom end of the fixing frame (7) is rotatably connected to a connecting block (8); a plurality of limit blocks (9) are fixedly installed on the inner wall of the fixing frame (2); a plurality of the limit blocks (9) are provided with slots (10) on the top; an auxiliary block (11) is fixedly connected to the side wall of the fixing frame (2); a shielding block (12) is movably connected to the top of the auxiliary block (11); a storage box (13) is fixedly installed on the top of the shielding cover (3); a rotating cover (14) is rotatably connected to one side of the storage box (13).
5. The early diagnosis kit for liver cancer that is easy to use and store according to claim 4, characterized in that: The size specifications of the surface of the shielding cover (3) are matched with the size specifications of the inner wall of the placement box (1); the bottom end of the clamping block (4) is clamped with the inner wall of the connecting groove (5); the size specifications of the bottom end of the clamping block (4) are matched with the size specifications of the inner wall of the connecting groove (5); and the top of the clamping block (4) is fixedly mounted with the bottom end of the shielding cover (3).
6. The early diagnosis kit for liver cancer that is easy to use and store according to claim 4, characterized in that: There are at least two fixing blocks (6), the two fixing blocks (6) are symmetrically distributed with the shielding cover (3) as the axis, the cross-sections of the two fixing blocks (6) are both in an "L"-shaped structure, the cross-section of the connecting ring (7) is in a "U"-shaped structure, and one side of the connecting block (8) is fixedly connected to the surface of the placement box (1).
7. The early diagnosis kit for liver cancer that is easy to use and store according to claim 4, characterized in that: The size of the surface of the limit block (9) is compatible with the size of the inner wall of the fixed frame (2), and the limit block (9) is a rubber block. The center of the slot (10) and the center of the limit block (9) are on the same straight line.
8. The early diagnosis kit for liver cancer that is easy to use and store according to claim 4, characterized in that: The side wall of the auxiliary block (11) is movably mounted on the inner wall of the placement box (1), and the auxiliary block (11) is a sponge block. The size of the surface of the auxiliary block (11) is compatible with the size of the inner wall of the placement box (1). The shielding block (12) is a rubber block, and the top of the shielding block (12) is fixedly connected to the bottom of the shielding cover (3).
9. The early diagnosis kit for liver cancer that is easy to use and store according to claim 4, characterized in that: The center of the storage box (13) and the center of the shielding cover (3) are on the same straight line, and the size specifications of the inner wall of the rotating cover (14) are compatible with the size specifications of the surface of the storage box (13).
10. The early diagnosis kit for liver cancer that is easy to use and store according to claim 4, characterized in that: A partition plate (15) is fixedly installed inside the storage box (13), and the size of the surface of the partition plate (15) is compatible with the size of the inner wall of the storage box (13).